There’s a lot to be optimistic about in the Conglomerates sector as 2 analysts just weighed in on The ExOne Company (XONE) and Intricon Corp (IIN) with bullish sentiments.
The ExOne Company (XONE)
In a report released today, Dan Drawbaugh from B.Riley FBR reiterated a Buy rating on The ExOne Company, with a price target of $12. The company’s shares closed yesterday at $7.36.
Drawbaugh wrote:
“Industrial-focused 3D printer manufacturer ExOne (XONE) reported positive 2Q19 results on the close. Second-quarter total revenue was up more than 40% Y/Y as printer shipment volume nearly doubled and printer ASP increased over 55% relative to 2Q18, offsetting expected softness in non-printer revenue. We continue to believe that XONE has one of the more compelling growth opportunities in the 3D printing space because of its technology leadership in binder jetting, a high-volume additive manufacturing process that targets industrial verticals like automotive and foundry. XONE’s recent product introductions and partnerships with industry 4.0 stakeholders should help support its continued growth, in our view.”
According to TipRanks.com, Drawbaugh is ranked #4141 out of 5229 analysts.
The ExOne Company has an analyst consensus of Moderate Buy, with a price target consensus of $12.
See today’s analyst top recommended stocks >>
Intricon Corp (IIN)
In a report released yesterday, Andrew D’silva from B.Riley FBR maintained a Buy rating on Intricon Corp, with a price target of $36. The company’s shares closed yesterday at $17.54, close to its 52-week low of $16.81.
D’silva commented:
“IntriCon (IIN) reported 2Q19 results, and posted a top-line/adj. EPS (exclude discontinued operations/impairment charges) of $29.3M/$0.03, versus our/ consensus’ estimates of $29.3M/$0.04 and $29.3M/$0.03, respectively. Revenue was in line with last month’s business update’s preannouncement (see note dated 7/19). The biggest variance: impairment charges tied to IIN’s DTC hearing aid business and losses from discontinued operations, related to the company’s UK divestiture, coming in above our estimates, which we subsequently excluded in adj. EPS, as we looked to provide a clean comparison without these one-time items. However, as IIN doesn’t provided non-GAAP figures, an accurate crosswalk for consensus isn’t available.”
According to TipRanks.com, D’silva is a 3-star analyst with an average return of 2.1% and a 37.1% success rate. D’silva covers the Healthcare sector, focusing on stocks such as Cumberland Pharmaceuticals Inc, EyePoint Pharmaceuticals Inc, and Sensus Healthcare Inc.
Currently, the analyst consensus on Intricon Corp is a Moderate Buy with an average price target of $36.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
